LONDON (AP) -- GlaxoSmithKline PLC says it has signed an agreement with Lonza for the Swiss company to manufacture a number of drug compounds.
Glaxo and Lonza said in a joint statement on Wednesday that Lonza will initially manufacture clinical trial batches of five compounds that are in phase 1 and 2 development at Glaxo.
The companies haven't released any details of the financial terms of the deal.
Glaxo shares are up 0.9 percent at 1,271 pence ($19.64) on the London Stock Exchange.
